Bavarian Nordic A/S (CPH:BAVA)

Denmark flag Denmark · Delayed Price · Currency is DKK
152.95
+0.40 (0.26%)
Apr 25, 2025, 4:59 PM CET
2.31%
Market Cap 11.90B
Revenue (ttm) 5.72B
Net Income (ttm) 987.98M
Shares Out 77.81M
EPS (ttm) 12.60
PE Ratio 12.14
Forward PE 9.56
Dividend n/a
Ex-Dividend Date n/a
Volume 127,722
Average Volume 263,304
Open 153.30
Previous Close 152.55
Day's Range 151.55 - 153.95
52-Week Range 123.30 - 300.00
Beta 1.38
RSI 48.85
Earnings Date May 9, 2025

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the Unite... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1992
Employees 1,605
Stock Exchange Copenhagen Stock Exchange
Ticker Symbol BAVA
Full Company Profile

Financial Performance

In 2024, Bavarian Nordic's revenue was 5.72 billion, a decrease of -19.06% compared to the previous year's 7.06 billion. Earnings were 987.98 million, a decrease of -33.03%.

Financial Statements

News

Bavarian Nordic's Chikungunya Vaccine Receives Recommendation from U.S. CDC's Advisory Committee on Immunization Practices (ACIP)

COPENHAGEN, Denmark, April 16, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACI...

9 days ago - GlobeNewsWire

Correction: Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S

COPENHAGEN, Denmark, April 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2024 was adopted. The Board of Directors' p...

16 days ago - GlobeNewsWire

Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S

COPENHAGEN, Denmark, April 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2024 was adopted. The Board of Directors' p...

16 days ago - GlobeNewsWire

Bavarian Nordic Trading At Great Value Levels With Upbeat 2025 Outlook

BVNKF now expects margin improvements from rabies/TBE vaccine production transfers to Denmark, starting in 2025. Also, their recently FDA-approved freeze-dried Jynneos vaccine and EU/US-approved chiku...

18 days ago - Seeking Alpha

Pharma tariff relief likely short-lived with sector-specific duties on the horizon

Pharmaceutical companies breathed a sigh of relief Wednesday after U.S. President Donald Trump revealed that they would not be subject to reciprocal tariffs — but that reprieve could prove fleeting. T...

22 days ago - CNBC

US FDA approves freeze-dried version of Bavarian Nordic's mpox, smallpox vaccine

Denmark's Bavarian Nordic said on Monday the U.S. Food and Drug Administration has approved a freeze-dried formulation of its mpox and smallpox vaccine.

25 days ago - Reuters

Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine

COPENHAGEN, Denmark, March 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the U.S. Food and Drug Administration (FDA) has approved the freeze-dried formulation of JYNNEOS® (Smallpox a...

25 days ago - GlobeNewsWire

Widely used drugs on US imports list from Europe

Widely used prescription medicines could get caught up in the Trump administration's tariff trade wars and EU retaliation.

5 weeks ago - Reuters

Bavarian Nordic A/S – Notice Convening Annual General Meeting

COPENHAGEN, Denmark, March 12, 2025 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held on

6 weeks ago - GlobeNewsWire

Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older

COPENHAGEN, Denmark, March 7, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has validated the marketing authorization ap...

7 weeks ago - GlobeNewsWire

Bavarian Nordic A/S (BVNKF) Q4 2024 Earnings Call Transcript

Bavarian Nordic A/S (OTCPK:BVNKF) Q4 2024 Earnings Conference Call March 5, 2025 8:00 AM ETCompany ParticipantsRolf Sass Sorensen - Head, Investor...

7 weeks ago - Seeking Alpha

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, March 5, 2025 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company's shares/related securities by persons holding manag...

7 weeks ago - GlobeNewsWire

Bavarian Nordic Publishes Annual Report 2024

Audited results confirm full-year revenue of DKK 5,716 million and EBITDA of DKK 1,603 million. Two new early-stage pipeline programs, Lyme disease and Epstein-Barr Virus (EBV), introduced.

7 weeks ago - GlobeNewsWire

Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older

COPENHAGEN, Denmark, February 28, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the European Commission has granted marketing authorization in Europe for VIMKUNYA® for active immunizatio...

2 months ago - GlobeNewsWire

Biological E in strategic pact with Danish co Bavarian Nordic to manufacture Chikungunya vax for global access

Hyderabad: Biopharma player Biological E (BE) entered into a strategic partnership with Danish vaccine maker Bavarian Nordic to manufacture the latter.

2 months ago - The Times of India

Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine

COPENHAGEN, Denmark, February 25, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced a strategic partnership with Biological E. Limited (BE) to expand access to Bavarian Nordic's chikungunya vacci...

2 months ago - GlobeNewsWire

Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older

COPENHAGEN, Denmark, February 14, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Food and Drug Administration (FDA) has approved VIMKUNYA™ (Chikungunya Vaccine, Recombinant) for ...

2 months ago - GlobeNewsWire

Bavarian Nordic Reports Preliminary 2024 Financial Results in Line with Upgraded Guidance and Guides for 2025

COPENHAGEN, Denmark, February 3, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced preliminary, unaudited financial results for 2024 and provided its financial guidance for 2025.

2 months ago - GlobeNewsWire

Bavarian Nordic – Completion of Share Buy-Back Program

COPENHAGEN, Denmark, January 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on January 9, 2025, has now been completed, reachin...

3 months ago - GlobeNewsWire

Bavarian Nordic Receives Positive CHMP Opinion for Chikungunya Vaccine for Persons Aged 12 and Older

COPENHAGEN, Denmark, January 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopte...

3 months ago - GlobeNewsWire

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

COPENHAGEN, Denmark, January 27, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 9, 2025, under which the Company will repurchase sha...

3 months ago - GlobeNewsWire

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

COPENHAGEN, Denmark, January 20, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 9, 2025, under which the Company will repurchase sha...

3 months ago - GlobeNewsWire

Bavarian Nordic Launches Planned Share Buy-Back Program of DKK 150 Million

COPENHAGEN, Denmark, January 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a share buy-back program of up to DKK 150 million as announced on December 11, 2024. The decisi...

3 months ago - GlobeNewsWire

Nigeria set to receive 11,200 doses of Mpox vaccine

The doses, manufactured by Bavarian Nordic, have been allocated to affected countries. The post Nigeria set to receive 11,200 doses of Mpox vaccine appeared first on Premium Times Nigeria .

4 months ago - Premium Times Nigeria

Bavarian Nordic Inks Mpox Vaccine Deal With Serum Institute

Bavarian Nordic A/S agreed to a deal with the world’s largest vaccine manufacturer, the Serum Institute of India Pvt, to make the Danish biotech firm’s mpox shot.

4 months ago - BNN Bloomberg